9 CFR 113 Readiness for Veterinary Biologics Serials

9 CFR 113 readiness means being able to explain why a particular veterinary biologic serial or subserial can—or cannot—enter the market. The useful deliverable is a connected evidence record: product and establishment status, the filed Outline of Production, concurrent preparation records, required tests, sampling, applicable holds, a human disposition, and subsequent inventory and distribution movements.

Under 113.1, Part 113 applies to each serial or subserial of a licensed biological product manufactured in a licensed establishment, and each serial or subserial in an imported shipment for distribution and sale. This guide concentrates on licensed-establishment operations. It does not provide product-specific laboratory methods, production protocols, acceptance thresholds, or clinical instructions.

The routing table is orientation, not a product-classification decision. Section 101.2 defines biological products through their intended use and immune-system or immune-response action, with additional provisions for analogous products. Have the regulatory owner resolve an uncertain product boundary before selecting a manufacturing or reporting workflow.

Start with the product and establishment, not a familiar trade name. Section 101.2 defines a licensed establishment by its unexpired, unsuspended, and unrevoked establishment license. Section 101.3 similarly defines a licensed biological product by preparation in a licensed establishment and an unexpired, unsuspended, and unrevoked product license. Record the relevant identifiers and status evidence in the serial index.

Under 114.8, an Outline of Production must be on file for each licensed product and each product authorized for importation for Distribution and Sale. Preparation in a licensed establishment must follow the filed Outline, subject to changes required under 114.8(f). Approval for filing is not APHIS endorsement of the product or its preparation methods.

Each licensee must review each Outline for accuracy and sufficiency at least annually and submit revisions necessary for regulatory compliance. Under 114.8(f), the Administrator may object to preparation methods based on previously unavailable information and require modification. Failure to comply can lead to product-license suspension after an opportunity for a hearing; preparation then stops until suspension is withdrawn.

Section 114.8 directs preparation of the Outline as prescribed in 114.9. Keep page control, signatures, and transmittal review in a regulatory-owned formatting checklist rather than improvising a filing package from the serial record. The Outline of Production glossary can support terminology, but it does not replace the actual filed document.

Avoid treating completed, finished, and released as synonyms. Under 101.3, completed product has reached final form and composition; finished product has also been bottled, sealed, packaged, and labeled as required; released product is finished product released for marketing after satisfactory compliance with all requirements. A warehouse status should preserve those distinctions.

The serial, subserial, fraction, Outline of Production, and Product Code Number definitions are in 101.3, not 101.2. A serial is the total quantity of completed product thoroughly mixed in a single container and identified by a serial number, subject to the section's combination-package proviso. Subserials are properly identified portions further processed at different times or under different conditions.

A fraction is a specific antigen, its antibodies, or its antitoxin constituting a product component. A Product Code Number is assigned by APHIS to each type of licensed biological product. As a practice, connect these product-level identifiers to the serial and each subserial without using the product code as a substitute for production identity.

Under 116.1, records must provide a complete accounting of establishment activities. They are made concurrently with successive development and preparation steps, including new products under development. They include dates, critical times, ingredient identities and quantities added or removed, and gains or losses throughout preparation.

Records must be legible, indelible, sufficiently detailed, and verified by the initials or signature of the person immediately responsible for the action. This provision does not impose a universal second-person signature. A site may establish additional review practices, but should not mislabel them as that requirement.

• Carry the parent serial and subserial identifiers into preparation, sample, laboratory, storage, and shipment records.
• Record actual quantities with units; distinguish containers from volume, mass, or other production measures.
• Capture a transfer as an origin, destination, quantity, time, and responsible-person entry—not merely a new location label.
• Keep original observations understandable when correcting an entry; explain the correction under the site's record procedure.
• At handoff, list unfinished work and missing evidence separately from completed preparation steps.

For imports, 116.1 also requires the permittee to maintain relevant detailed records at its place of business, including importation documents, sampling records, test summaries, shipping records, and inventory/disposition records. Authorized alternative record locations require an addendum to the plot plan legend identifying location, storage conditions, and inspection access. An internal storage decision alone is not that authorization.

Build a product-specific test register from the filed Outline and applicable Standard Requirements. Under 113.4, applicable Standard Requirement methods and procedures must be followed unless the Administrator grants an exemption and it is noted in the filed Outline. The Outline designates the evaluation methods and procedures. An internal risk assessment or management signature cannot create that exemption.

Section 113.5 prohibits release before completion of the prescribed tests to establish purity, safety, potency, and efficacy. A competent manufacturer employee must observe all critical testing periods. Required test results must be submitted to APHIS. Newly developed methods approved by APHIS also have the applicability described in 113.5(e); a product not satisfactory under those methods cannot be released.

The definitions in 101.5 explain what each regulatory designation means. Under 113.5(d), reasons for No Test and inconclusive designations belong in the test records. Neither is final. Repetition or further testing must respect the applicable filed methods and established testing path. If a product with either designation is not further tested, unsatisfactory becomes the final conclusion.

A useful register shows the required test, applicable method revision, serial/subserial scope, sample identifier, execution dates, critical-period observation evidence, designation, reasons where applicable, further-test reference, and submission reference. Keep the original and later tests as separate linked records. Replacing an initial No Test entry with a satisfactory result destroys the explanation of what happened.

Distinguish an analyst's observation, the regulatory test designation, and readiness for disposition. A satisfactory designation is final for that test; it does not establish that other required tests, records, or applicable holds are complete. Conversely, a missing attachment is not automatically an inconclusive test: describe the actual evidence gap rather than inventing a laboratory designation.

Under 113.3, licensees and permittees furnish representative samples as prescribed. Prerelease selection is performed by a Department, licensee, or permittee employee designated by the Administrator. The selecting person marks samples for identification; they are packaged and forwarded to the National Veterinary Services Laboratories, subject to the section's Department forwarding option.

Sample selection depends on the product and presentation. The final-container numbers in 113.3(b) are category-specific, not a universal sample allowance. For applicable bulk samples of completed liquid product, the number of samples and minimum quantity in each belong in the filed Outline. Comparable samples are used for similar APHIS, licensee, and permittee tests.

• Document the applicable sampling provision and Outline reference before preparing a sample instruction.
• Connect selection authorization, sample identity, parent serial/subserial, packaging, and dispatch evidence.
• Separate prerelease submissions, testing consumption, reserve stock, and any additional samples in the quantity ledger.
• Maintain evidence of reserve location and storage; do not treat reserved units as available commercial inventory.

Section 113.3(e) separately addresses reserve samples: random selection from final containers by a designated employee, representative and adequate samples, and storage in a special compartment under refrigeration at the label-recommended temperature for six months after labeled expiration. They must be delivered to APHIS on request. Use the applicable regulatory quantities rather than the illustrative arithmetic later in this guide.

Under 113.6, the Administrator may cause a product to be examined and tested. In that case, the licensee or permittee withholds it from the market until a determination is made. This specific hold is not a statement that every serial universally needs individual APHIS approval before release.

Keep an APHIS-initiated testing hold distinct from an internal hold for unfinished testing or missing records. Log the affected scope, trigger, communication reference, and determination evidence. Section 113.6 also requires consideration of final licensee and APHIS test results and prohibits market release of a serial or subserial found unsatisfactory by a required test.

Under 116.7, the licensee maintains detailed records of all tests on each serial and subserial. Summaries prepared from those records must be submitted to APHIS on Form 2008 or an acceptable equivalent before release. Keep detailed records, the summary, and submission evidence connected; a summary is not a replacement for the underlying tests.

Sections 116.1 and 116.8 require Part 116 records other than disposition and adverse-event records to be completed before any portion of a serial is marketed in the United States or exported. The exceptions accommodate continuing post-release records; they do not excuse unfinished preparation or test records.

A practical disposition page identifies exactly which serial/subserials, presentation, and quantities the reviewer is deciding about. It cites the final test register, completed preparation record, sampling evidence, submission reference, and any relevant APHIS determination. It also separates commercial units from retained samples, consumed units, and destroyed stock.

Record the human conclusion as release, continued hold, or another supported disposition, with its rationale. Use an explicit evidence-gap list for a hold. Avoid a single unchecked assertion that the serial is compliant, and do not treat the date of a satisfactory test as the release date. The reviewer needs the complete release context, not just a passing-result count.

Fictional Alder Veterinary Biologics operates establishment DEMO-E17 and prepares Fictional Product Alder-B, a veterinary biologic with internal product-code alias DEMO-PC-B. These are not real license or APHIS code numbers. Serial AB-260910 comprises 10,000 finished containers. Its properly identified portions, subserials AB-260910-A and AB-260910-B, were further processed at different times and contain 6,000 and 4,000 containers respectively.

The training baseline is filed Outline alias OP-AB revision 06. Product and establishment status are stipulated current, the annual Outline review is dated August 3, 2026, and both subserials bear expiration September 30, 2027. Preparation and packaging records identify the parent serial, subserial operations, responsible people, dates, critical times, ingredients, and quantity movements.

The allocation balances: 40 consumed + 60 retained + 40 destroyed + 9,860 commercial = 10,000. These categories are mutually exclusive. The commercial quantity is a disposition population, not an additional quantity to add to finished output. The actual sample-selection requirements would still need separate product-specific confirmation.

The signed rationale states that required testing and records are complete, the No Test history and repeat are linked, the APHIS testing hold has a documented determination, and the summaries preceded release. It identifies the actual stock locations and excludes noncommercial allocations. Both subserials are complete before any marketing in this example.

One unresolved item will emerge during the later distribution trace: the onward destination of 120 A containers cannot be verified. That later problem does not rewrite the September 21 decision. It creates a new assessment, action record, and notification decision linked to the same serial.

Under 116.2, records show the quantity and location of each biological product being prepared, in storage, and in distribution channels. Each licensee, distributor, and permittee maintains detailed disposition records, satisfactory in form to the Administrator, showing sale, shipment, or other disposition.

For implementation, maintain two connected views. A movement ledger explains what happened over time. A stock-position view explains where quantities are now and their status. Cumulative released, shipped, and returned totals are lifecycle measures; they cannot be added to current stock as if each were another physical population.

Continuing the same fictional serial, Alder ships 4,000 A containers to Fictional Cedar Distribution on September 22 and 3,000 B containers to Fictional Orchard Distribution on September 23. Cedar returns 100 A containers on October 2; those enter a segregated returns location, not available stock. No other movement is assumed before the October 6 trace.

Cumulative shipments are 7,000; cumulative returns are 100; net distribution is 6,900. Commercial accounting is 2,860 unshipped + 100 returned + 6,900 distributed = 9,860 released. Full physical accounting is 9,920 current stock + 40 consumed + 40 destroyed = 10,000. A status change to hold will change none of those quantities.

Use shipment identifiers, consignee references, dates, quantities, and serial/subserial identity as practical tracing fields. Preserve the original shipment when recording a return. A balanced ledger demonstrates quantity accounting, but it does not prove that every downstream location is known.

Make the serial index a navigation aid, not a replacement record. A person unfamiliar with the run should be able to open the filed baseline, executed records, original test evidence, submissions, disposition, and movements. Record document revisions and locations precisely enough to distinguish a current instruction from the version used for this serial.

At 09:00 on October 6, the fictional team starts a 30-minute retrieval exercise. This is an internal target, not a legal response period. By 09:10, another reviewer has opened the source records and reproduced the 10,000-container balance. By 09:20, distributor evidence accounts for Orchard's 3,000 B containers and Cedar's 3,900 net A containers.

Cedar's 3,900 consists of 2,780 at its warehouse, 1,000 transferred to an identified fictional clinic, and 120 recorded as transferred onward without a verifiable recipient. The quantity equation balances: 2,780 + 1,000 + 120 = 3,900. The location trace does not. Do not relabel the 120 as missing physical quantity or falsely assign them to Cedar's warehouse.

At 09:24, the fictional regulatory lead determines that the unexplained distribution destination indicates a possible distribution problem. The scenario records immediate APHIS notification and a human decision to hold the remaining 2,860 warehouse containers; the 100 returned containers remain held. These are training records only, not real agency communications. At 09:30, the 120-container destination remains unresolved, assigned to the distribution lead for further retrieval.

The exercise demonstrates accessible release records and reproducible arithmetic, but fails complete downstream tracing. Keep that failure visible. Record the missing dispatch evidence, contact attempts, current actions, owner, and next review time without declaring the trace closed merely because every container fits the ledger.

Section 101.2 defines an adverse event broadly: an unfavorable, unintended observation in animals after any use of a biological product, whether or not the cause is known, including suspected lack of expected efficacy. For diagnostic products it includes performance failure hindering an expected correct diagnosis. Its adverse event report definition requires an identifiable first-hand reporter, animal, biologic product, and one or more adverse events.

Under 116.9, licensees and permittees keep a detailed record of every adverse event report received for products they produce or distribute. Record receipt first, then preserve the original information, follow-up, assessment, and reporting reference. Do not wait for proof of causation before capturing the report.

Assess the triggers separately. The immediate product-problem trigger does not require an event first to satisfy the product-related, serious, and unexpected combination. Equally, a report outside the immediate categories still belongs in the reporting process. Do not reset first receipt to the date a quality or regulatory reviewer finishes the assessment.

For arithmetic illustration, a report first received October 6, 2026 reaches a 90-calendar-day interval on January 4, 2027: October 7–31 contributes 25 days, November 30, December 31, and January 1–4 another four. Set an internal submission target earlier than that boundary and retain the original receipt date. This calculation does not create a waiting period when immediate reporting applies.

Use the USDA calendar-day rule here. Do not import FDA animal-drug reporting schedules or record-retention periods into the biologics record. Intake staff should know which human licensee or permittee contact owns assessment and reporting, including how to reach an alternate when the usual owner is unavailable.

116.5(b) requires immediate notification if indications raise questions about product purity, safety, potency, or efficacy, or if there may be a preparation, testing, or distribution problem. The duty applies to the licensee, permittee, or foreign manufacturer and includes the circumstances and action taken, if any.

This is broader than an adverse-event intake workflow. A testing concern or distribution discrepancy can trigger it without an animal-event report. In the fictional trace, the responsible person records a possible distribution problem and notification while the 120-container destination remains unresolved. Investigation completion is not substituted for immediate notification.

• Preserve the first facts and the time they became known; distinguish observation from interpretation.
• Identify the potentially affected product, serial/subserial, locations, and quantities, including unknowns.
• Record the human trigger assessment and the person responsible for notifying APHIS.
• Describe actions actually taken, not proposed actions presented as complete.
• Keep communication evidence, subsequent information, and the next review point linked to the original issue.

Section 116.5(a) also requires accurate and complete reports when requested by the Administrator, including reports concerning development, preparation, market suspensions, and recalls. Unless otherwise authorized, the supporting records are maintained in each establishment. A practical notification worksheet should therefore point to the same underlying evidence used for the serial and distribution records.

Maintain usable contact instructions and an absence-cover arrangement. A suggested worksheet can organize known facts and gaps, but it should not require every field to be complete before the responsible person addresses an immediate-notification trigger. Keep the reporting decision separate from whether stock is released, held, returned, or otherwise disposed of.

Do not apply one retention period to every serial-related record. 116.8 requires records to be retained for two years after product expiration, or longer if required by the Administrator. Section 116.9 separately requires adverse-event records for three years after report receipt. Maintain both anchors in the retention schedule.

These dates illustrate separate clocks, not permission for automatic destruction. As a practice, when one document supports multiple record families, preserve it through the latest applicable retention endpoint and check for any longer requirement before disposition. Physical sample retention is not a substitute for record retention, and vice versa.

Test retrieval over the retention period: can another authorized reviewer locate, open, read, and relate the original evidence to its serial? Include superseded Outline pages used for the serial, historical test methods, submission evidence, and later distribution and adverse-event records. A surviving index entry does not establish that the underlying record remains usable.

Treat a proposed expiration extension as a separate regulatory review, not a warehouse edit. As a review package, assemble potency-evaluation evidence, the product's licensed-premises movement history, any licensed-to-licensed transfers, prior extensions, and applicable authorization. Have regulatory establish the permissible action before a person changes dating or related retention anchors. This checklist is not an extension authorization.

Keep the serial record open to later facts without altering its historical release decision. The fictional September release remains a dated decision on its evidence; the October distribution concern creates a separate action and notification trail. The unresolved 120-container destination stays visible until supported evidence resolves it.

• At each handoff, name the current stock position, status, evidence gaps, owner, and next action.
• Recheck Outline review dates and product/establishment status through the responsible regulatory process.
• Exercise one backward trace to original test and preparation records and one forward trace into distribution.
• Review reporting clocks and retention anchors independently of commercial inventory status.
• Close an item only against evidence; a balanced quantity total or completed task list is not proof of a complete trace.